163 related articles for article (PubMed ID: 10570064)
1. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Dodds HM; Rivory LP
Mol Pharmacol; 1999 Dec; 56(6):1346-53. PubMed ID: 10570064
[TBL] [Abstract][Full Text] [Related]
2. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Camps P; Cusack B; Mallender WD; El Achab RE; Morral J; Muñoz-Torrero D; Rosenberry TL
Mol Pharmacol; 2000 Feb; 57(2):409-17. PubMed ID: 10648652
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
Dodds HM; Hanrahan J; Rivory LR
Anticancer Drug Des; 2001; 16(4-5):239-46. PubMed ID: 12049482
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
Hyatt JL; Tsurkan L; Morton CL; Yoon KJ; Harel M; Brumshtein B; Silman I; Sussman JL; Wadkins RM; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():247-52. PubMed ID: 16257398
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
6. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
Morton CL; Wadkins RM; Danks MK; Potter PM
Cancer Res; 1999 Apr; 59(7):1458-63. PubMed ID: 10197614
[TBL] [Abstract][Full Text] [Related]
7. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase.
Berman HA; Leonard K
Mol Pharmacol; 1992 Feb; 41(2):412-8. PubMed ID: 1538717
[TBL] [Abstract][Full Text] [Related]
8. The nature of the inhibition of camel retina acetylcholinesterase (EC 3.1.1.7) activity by tetrahydroaminoacridine.
al-Jafari AA
J Ocul Pharmacol Ther; 1996; 12(4):503-14. PubMed ID: 8951687
[TBL] [Abstract][Full Text] [Related]
9. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Wadkins RM; Silman I; Sussman JL; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():153-7. PubMed ID: 16289500
[TBL] [Abstract][Full Text] [Related]
10. In vitro protection of acetylcholinesterase and butyrylcholinesterase by tetrahydroaminoacridine. Comparison with physostigmine.
Galli A; Mori F; Gori I; Lucherini M
Biochem Pharmacol; 1992 Jun; 43(11):2427-33. PubMed ID: 1610407
[TBL] [Abstract][Full Text] [Related]
11. Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands.
Szegletes T; Mallender WD; Rosenberry TL
Biochemistry; 1998 Mar; 37(12):4206-16. PubMed ID: 9521743
[TBL] [Abstract][Full Text] [Related]
12. New tacrine-acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer's disease.
Chufarova N; Czarnecka K; Skibiński R; Cuchra M; Majsterek I; Szymański P
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1800050. PubMed ID: 29870588
[TBL] [Abstract][Full Text] [Related]
13. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate.
Rosenberry TL; Mallender WD; Thomas PJ; Szegletes T
Chem Biol Interact; 1999 May; 119-120():85-97. PubMed ID: 10421442
[TBL] [Abstract][Full Text] [Related]
14. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect.
Szegletes T; Mallender WD; Thomas PJ; Rosenberry TL
Biochemistry; 1999 Jan; 38(1):122-33. PubMed ID: 9890890
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.
Fang L; Kraus B; Lehmann J; Heilmann J; Zhang Y; Decker M
Bioorg Med Chem Lett; 2008 May; 18(9):2905-9. PubMed ID: 18406135
[TBL] [Abstract][Full Text] [Related]
16. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cholinesterase activity by tetrahydroaminoacridine and the hemisuccinate esters of tocopherol and cholesterol.
Chelliah J; Smith JD; Fariss MW
Biochim Biophys Acta; 1994 May; 1206(1):17-26. PubMed ID: 8186246
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
19. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Thiratmatrakul S; Yenjai C; Waiwut P; Vajragupta O; Reubroycharoen P; Tohda M; Boonyarat C
Eur J Med Chem; 2014 Mar; 75():21-30. PubMed ID: 24508831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
